A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability As Well As Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects with Alpha1-Antitrypsin Deficiency

The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).

Start Date13 Aug 2021

Sponsor / Collaborator

Grifols Therapeutics, Inc.

NCT04547140

/ TerminatedPhase 2

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19

The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus placebo plus SMT in hospitalized participants with COVID-19.

Start Date29 Jan 2021

Sponsor / Collaborator

Grifols Therapeutics, Inc.

NCT04495101

/ CompletedPhase 2

A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19

The primary objective of the study is to determine if Prolastin plus SMT can reduce the proportion of subjects dying or requiring intensive care unit (ICU) admission on or before Day 15 or who are dependent on invasive mechanical ventilation on Day 15 versus SMT alone in hospitalized subjects with Coronavirus disease 2019 (COVID-19).

Start Date29 Jul 2020

Sponsor / Collaborator

Instituto Grifols SA

100 Clinical Results associated with Alpha1-proteinase inhibitor(Grifols SA)

100 Translational Medicine associated with Alpha1-proteinase inhibitor(Grifols SA)

100 Patents (Medical) associated with Alpha1-proteinase inhibitor(Grifols SA)

1,323

Literatures (Medical) associated with Alpha1-proteinase inhibitor(Grifols SA)

01 Apr 2025·Phytomedicine

Apigenin alleviates inflammation as a natural IRAK4 inhibitor

Article

Author: Ji, Kailong ; Gongpan, Pianchou ; Zhang, Yufei ; Wang, Xue ; Xu, Tingting ; Li, Jia ; Sun, Yili ; Kong, Lingmei ; Chen, Hongman ; Geng, Chang-An ; Song, Qishi

BACKGROUNDUncontrolled inflammation is a key factor in the development of many diseases, and targeting pivotal kinases involved in the inflammatory response, such as interleukin-1 receptor-associated kinase 4 (IRAK4), holds promise for the treatment of inflammatory conditions. Apigenin (Api) is a popular element in numerous plants, possessing anti-inflammatory properties. Many studies have shown that Api modulates NF-κB signaling and MAPK cascade to reduce inflammation, but the exact mechanisms by which Api regulates these pathways remain unclear.PURPOSEThe aim of this study was to investigate the role of Api on acute inflammation and its specific mechanism in mediating inflammation.METHODSThe dextran sulfate sodium (DSS) induced ulcerative colitis (UC) model and LPS induced acute inflammation mouse model were established to investigate the anti-inflammatory effects of Api. Subsequently, the anti-inflammatory activity of Api was validated in vitro and vivo by RNA-seq, qPCR, Western blot, cytokine ELISA, immunofluorescence and histological analysis. A series of experiments were performed to study the effects of Api on IRAK4, including ADP-Glo™ kinase assay, surface plasmon resonance (SPR), cellular thermal shift assay (CETSA), and molecular docking simulation. The targeting of Api to IRAK4 was verified by IRAK4 inhibitor and siRNA.RESULTSOral administration of Api significantly ameliorated inflammatory conditions in the LPS induced acute inflammation and DSS induced UC mouse models. Furthermore, Api inhibited the expression of interleukin and chemotactic factor genes and downregulated the immune response of macrophages at the transcriptome level. Mechanistically, Api acted as a novel IRAK4 inhibitor, inhibiting kinase activity by direct binding to IRAK4 (Kd = 4.78 μM) with an IC₅₀ of 1.74 μM, interfering with extracellular signaling to the NF-κB and MAPK pathways, and reducing the expression of pro-inflammatory factors in an IRAK4 dependent manner.CONCLUSIONIn this study, Api was identified for the first time as a natural IRAK4 inhibitor that suppresses cytokine signaling pathways and modulates the immune response at the level of the transcriptome. The results provided valuable insights into the specific mechanism of Api inhibition of inflammatory activation and shed light on opportunities for the development of novel IRAK4 inhibitors based on Api, which is found in various plants.

13 Feb 2025·Journal of Medicinal Chemistry

Development of a Novel Human Serum Albumin-Based Tool for Effective Drug Discovery: The Investigation of Protein Quality and Immobilization

Article

Author: Molnár, Zsófia ; Koplányi, Gábor ; Kenéz, Balázs ; Katona, Gábor ; Balogh, György T. ; Decsi, Balázs ; Horváth, Péter ; Balogh-Weiser, Diána

The binding ability of human serum albumin (HSA) on active pharmaceutical ingredients (APIs) is one of the most important parameters in the early stages of drug discovery. In this study, an immobilized HSA-based tool was developed for the rapid and easy in vitro screening of API binding. The work explored the serious incompleteness in the identification of HSA used for in vitro screening published in the last five years. To mitigate this problem, a comprehensive analysis and immobilization studies were performed on the most used HSA types. Serious differences in the colloidal stability of HSAs and their API binding ability on a selected set of APIs were observed. HSAs were immobilized on magnetic nanoparticles with glutardialdehyde (GDA) or cyclohexyl-diglycidyl ether (CDGE) linkers, which have never been used for HSA immobilization before. The HSA-MNP-CDGE complexes achieved a higher immobilization yield and preserved API binding ability; however, the esterase-like enzymatic activity of HSA reduced significantly.

02 Jan 2025·Drug Development and Industrial Pharmacy

Solid dispersion of alectinib HCl: preclinical evaluation for improving bioavailability and establishing an IVIVC model

Article

Author: Jadhav, Ajinkya ; Saha, Sumit Kumar ; Singh, Romi ; Dubey, Kiran ; Panigrahy, Bala Krishna ; Jhanana Kailash, Some ; Arya, Vipin ; Joshi, Amita

OBJECTIVEAlectinib HCl (ALB-HCl) is a BCS class IV molecule with low solubility and low oral bioavailability. Owing to its low bioavailability, a high dose of ALB-HCl is recommended with food to meet clinical efficacy. Thus, there is a need for a delivery system to overcome the bioavailability concerns.METHODSThree solid dispersion (SD) formulations (I, II, and III) were evaluated for in-vitro dissolution and in-vivo pharmacokinetics (PK) study in Wistar rats. An in-vitro and in-vivo correlation (IVIVC) model was developed to establish a relationship between in-vitro dissolution data and in-vivo PK data. The formulations were subjected to stability studies.RESULTSAll formulations showed enhanced dissolution in all the media except Formulation I in FaSSIF media. In-vivo PK studies displayed that Formulation I was inferior to API alone. Formulations II and III (amorphous SD [ASD]) exhibited two-fold higher C_max and AUC_0-last than API alone. Level A IVIVC model was established for C_max and AUC_0-last with an acceptable % prediction error (PE). When evaluated for external predictability, the model was found validated for C_max (% PE <10%), however, it was inconclusive for AUC_0-last (%PE -14.03). Stability studies showed ASD formulations were stable during storage.CONCLUSIONA stable ASD formulation of ALB-HCl was successfully developed with improved bioavailability. Developing an IVIVC model can act as a surrogate to predict in-vivo performance. The selection of formulation components in ASD shall be rationalized for bioavailability and stability before clinical evaluation.

News (Medical) associated with Alpha1-proteinase inhibitor(Grifols SA)

12 Sep 2024

·healthcare-digital.com

Grifols & Orange Business Launch Egypt Plasma Project

Grifols' Cairo project is part of a national initiative to achieve self-sufficiency in plasma-derived medicines. Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt Global healthcare company Grifols is working with French telecoms giant Orange to create a sustainable supply of essential therapeutics for life-threatening diseases in Egypt. Orange Business – the enterprise division of telecoms company, Orange Group – has completed the initial stage of a new data centre and communications infrastructure in Cairo, for Grifols Egypt for Plasma Derivatives (GEPD). GEPD is a joint venture between Grifols and Egypt's National Service Projects Organisation (NSPO), which manufactures military and civilian products and provides contracting services. The project is part of a national initiative to achieve self-sufficiency in plasma-derived medicines -- vital treatments extracted from blood plasma for various serious medical conditions. Partnership to boost Egyptian healthcare Grifols, a specialist in plasma-derived medicines, is seeking to interconnect critical healthcare facilities, including a plasma laboratory, co-location data centre, plasma warehouse, 20 plasma donation centres, and a state-of-the-art manufacturing facility. Orange Business is providing co-location services, which allows GEPD to house its servers in Orange's data centre. The company is also supplying communication services and support with equipment procurement. The networked healthcare infrastructure is designed to ensure efficient operations and “the timely delivery of plasma-derived medicines to patients in need”, said Dr Ahmed Serag, Chief Strategy and Projects Officer at GEPD. Kristof Symons, CEO International at Orange Business, said: "Our technical skills, experienced resources, and global knowledge were pivotal in enabling Grifols to replicate its global business model in Egypt. This project shows how Orange Business can support its customers in creating a positive impact in today's society." About Grifols Multinational healthcare company Grifols was founded in 1940 in Barcelona, Spain employs 24,000 people worldwide, and specialises in the production of plasma-derived medicines and the development of diagnostic solutions. Its core activities include plasma collection, the manufacture of protein therapies derived from plasma, and fractionation, a process that separates a mixture into two or more fractions with different chemical and physical properties. Grifols is conducting clinical trials for its Alzheimer's treatment , a plasma-based therapy aimed at slowing cognitive decline in patients with mild to moderate Alzheimer's disease. The company is also researching treatments for liver diseases and immunodeficiencies. Among Grifols' products are Gamunex, an immune globulin therapy used to treat primary immunodeficiency, and Prolastin, used in the treatment of alpha-1 antitrypsin deficiency. The firm also produces albumin solutions for fluid replacement and coagulation factors for haemophilia treatment. In the diagnostic sector, Grifols offers blood typing systems and infectious disease screening tools. The company operates a network of plasma donation centres, primarily in the US, which form a crucial part of its supply chain for plasma-derived therapies.

15 Nov 2023

·www.globenewswire.com

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenousThis first in-human subcutaneous approach to treating alpha1-antitrypsin deficiency, if proven successful in clinical trials, could give patients the convenience and flexibility to administer their medication from home BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SC) alpha1 antitrypsin (AAT) treatment being compared to Liquid Alpha1-Proteinase Inhibitor (Human) intravenous (IV). Alpha1-antitrypsin deficiency (also known as alpha-1) is an underdiagnosed1 genetic disorder that occurs when a patient has low levels of AAT, a protective protein that safeguards the lungs. Augmentation therapy with IV AAT is the standard medical treatment option for patients with severe AAT deficiency and emphysema. If proven successful in clinical trials, a SC option could provide alpha-1 patients the ability to independently administer AAT therapy from home, allowing for greater convenience and flexibility. In this multi-center, single-dose and repeat-dose study over eight weeks, Cohort 1 has been completed and demonstrated no safety issues with Alpha-1 15% that would prevent the study from moving forward into Cohort 2. “A subcutaneous option would be a first for alpha-1 patients, providing more freedom when it comes to managing their AAT deficiency by allowing patients to administer their medication from the comfort of their own home. We are pleased to announce this milestone during Alpha-1 Awareness Month, contributing to raising further visibility about this rare disease,” said Jörg Schüttrumpf, Chief Scientific Innovation Officer, Grifols. “We look forward to moving this study into Cohort 2. Grifols has a strong commitment to the alpha-1 community and continues to innovate to find additional treatment options for patients living with this disease, in addition to more convenient alpha-1 testing alternatives such as AlphaID™ At Home, our recently launched direct-to-consumer genetic health risk service.” “During Alpha-1 Awareness month, we are excited to share this exciting news to the Alpha-1 community of a new clinical trial advancement in Alpha-1. We are thrilled that Grifols has completed Cohort 1 in clinical study of Alpha-1 15% and moving forward into Cohort 2. This study evaluating first-in-human subcutaneous dosing option for Alpha-1 patients could provide a new option that could easily be administered from their own homes,” said Scott Santarella, Alpha-1 Foundation President and CEO. About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2022, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information, please visit www.grifols.com MEDIA CONTACT:Media Press Officemedia@grifols.com Tel. +34 93 571 00 02 INVESTORS: Investors Relations Department & Sustainabilityinversores@grifols.com - investors@grifols.com Tel. +34 93 571 02 21 LEGAL DISCLAIMER The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group 1 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900. doi:10.1164/rccm.168.7.818

23 Oct 2023

·www.prnewswire.com

Body Kitchen Announces Commitment to Seafood Ingredients in Green-Lipped Mussel & Elastin Supplements

Marine nutraceuticals, Pro Elastin and Pro Mobility, tackle skin elasticity and joint health CRANBURY, N.J., Oct. 23, 2023 /PRNewswire/ -- Body Kitchen, a premium natural supplement company dedicated to promoting well-nourished bodies, announced its commitment to using first-class, sustainably harvested ingredients in its popular and expanding lineup of marine nutraceuticals, including: Pro Elastin – skin elasticity formula features Prolastin®, bio-diverse marine elastin peptides from Boulogne-sur-Mer, France. Pro Mobility – joint health formula features Biolane™ pollution-free whole green-lipped mussel extract from New Zealand. The leading brand in elastin supplements, Body Kitchen was first-to-market with a high-potency, marine elastin peptide formula delivering optimal absorption without a 'fishy' odor. An advanced extraction process uses enzymes in place of chemicals to preserve the proprietary peptides' naturally high levels of antioxidants. Following the success of Pro Elastin, the company released Pro Mobility with whole green-lipped mussel extract, flash-frozen to retain its naturally occurring nutrient profile, including omega-3 fats, amino acids, vitamins, and minerals. Aquatic ingredients contain bioactive molecules not found in alternative sources, often with better digestibility and tolerance. State-of-the-art technologies preserve optimal potency and freshness, creating palatable, consumer-first ingredients that are sustainably produced and harvested. "Seafood provides some of the most nutritious, concentrated sources of macro and micro-nutrients," says Ravi Gogineni, VP of Product Development. "Through our sourcing of high-quality, efficacious, sustainably harvested marine ingredients from around the world, we can make their health benefits a reality for millions of people." In the next 10 years, the global marine supplements market is predicted to swell 8.1%, according to market research provider, Fact.MR. Body Kitchen is buoyed by deep industry knowledge, global partnerships, and economies of scale, making its marine nutraceuticals an appealing choice for consumers seeking the health benefits of fish in palatable, convenient forms. The company operates an ever-evolving portfolio of premium supplement brands, including its namesake Body Kitchen, Pro-Mobility, and Exceed. Driven by a core set of values that prioritizes quality, science and innovation, the family-run company is focused on being inclusive of a wide range of health challenges, consumer preferences, and market segments. Body Kitchen's Pro Elastin and Pro Mobility are available on the store site and on Amazon. Press Contact Brooke Place 630-414-1047 SOURCE Body Kitchen

100 Deals associated with Alpha1-proteinase inhibitor(Grifols SA)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Alpha1-proteinase inhibitor(Grifols SA)	B02AB02	DB00058

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alpha 1-Antitrypsin Deficiency	Japan	OrphanPacific, Inc.	22 Jan 2021
Pulmonary Emphysema	United States	Grifols Therapeutics, Inc.	02 Dec 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	Spain	Instituto Grifols SA	29 Jul 2020
Diabetes Mellitus, Type 1	Phase 2	United States	Grifols Therapeutics, Inc.	01 Mar 2014
HIV Infections	Phase 2	United States	Grifols Biologicals, Inc.	01 Apr 2012
COVID-19	Discovery	Spain	Instituto Grifols SA	29 Jul 2020
Alpha 1-Antitrypsin Deficiency	Discovery	United Kingdom	Grifols Therapeutics, Inc.	01 Jun 2006
Alpha 1-Antitrypsin Deficiency	Discovery	United States	Grifols Therapeutics, Inc.	01 Jun 2006
Cystic Fibrosis	Discovery	-	Grifols Therapeutics, Inc.	01 Dec 2003
Emphysema	Discovery	United Kingdom	Grifols Therapeutics, Inc.	01 Dec 2003
Emphysema	Discovery	Denmark	Grifols Therapeutics, Inc.	01 Dec 2003
Emphysema	Discovery	Sweden	Grifols Therapeutics, Inc.	01 Dec 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02947087 (CTgov)	Phase 1/2	Pancreatitis, Chronic	48	Prolastin-C (Prolastin-C)	elsntnitqw(dgdhukjcaj) = ryvynmpcga fezkzcgdwh (kcvfafefch, fqceypiopi - oqlfaqdrgw) View more	-	09 May 2023
				Placebo (Placebo)	elsntnitqw(dgdhukjcaj) = lqyzeiuhgl fezkzcgdwh (kcvfafefch, unurrmvurm - blytyizibh) View more
NCT04547140 (CTgov)	Phase 2	COVID-19	57	Standard Medical Treatment	ojyguyciss(fxjaqsriqx) = qqzjqgekbq osqiyfqvqu (rttquczqbf, vjaqltigjh - himchxolpd) View more	-	22 Mar 2023
NCT02870348 (GTI1401-OLE, CTgov)	Phase 1/2	Alpha 1-Antitrypsin Deficiency	4	Alpha-1 MP	hpafokddwd(tgrurlmfgu) = vuqlgmdmvo yqfklwefnf (gvfjsxwcrt, clrdcaghgn - jbiefdyvps) View more	-	21 Mar 2022
NCT02093221 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	76	180 mg/kg Alpha1-PI (Alpha1-PI 180 mg/kg/wk, 26 Weeks)	jhagrzeits(nyofvsalkt) = lwrzobxbuk azyqjvybtm (dnqwqnhhdg, tdjikngotq - vkqasnwvok) View more	-	19 Apr 2018
				180 mg/kg Alpha1-PI (180 mg/kg/wk Alpha1-PI, 13 Weeks)	jhagrzeits(nyofvsalkt) = ywmexzpigw azyqjvybtm (dnqwqnhhdg, ccuwooollm - eroeopoaao) View more
NCT02282527 (CTgov)	Phase 2/3	Alpha 1-Antitrypsin Deficiency	32	Alpha1-PI (Liquid Alpha₁-PI)	glghgsnave(pnjucwxjay) = zyljztbcqb rrogmxjuab (coqlftegoz, bdwyrpsbzx - tkrnfgesfb) View more	-	13 Mar 2017
				Prolastin-C (Prolastin-C)	glghgsnave(pnjucwxjay) = nkczckldsc rrogmxjuab (coqlftegoz, scpykrpdep - jbsobclqqg) View more
NCT01936896 (VCU-α1RT \| VCU-Alpha1RT, CTgov)	Phase 1/2	ST Elevation Myocardial Infarction \| Acute myocardial infarction	10	Alpha 1-Antitrypsin	(mwzfsoxell) = awlvwebrne axyvqlgmpd (owrqsyyqdw, fwmyyjsbno - mvltjkqxgt) View more	-	12 Feb 2016
NCT00295061 (Pubmed)	Phase 3	Alpha 1-Antitrypsin Deficiency	24	Prolastin-C	firzeuirga(htfkdslejy) = uqxqkgklfj ttxhmazezo (tzvkaibjyl )	-	30 Sep 2010
				Prolastin	firzeuirga(htfkdslejy) = rivqcpqcli ttxhmazezo (tzvkaibjyl )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis